Flagship Pioneering Inc. Denali Therapeutics Inc. Transaction History

Flagship Pioneering Inc.

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	SELL	$15.83 - $23.35 $15.1 Million - $22.3 Million	-955,452 Reduced 41.18%	1,364,516 $28 Million
Q4 2023 Feb 14, 2024	SELL	$16.2 - $23.18 $4.86 Million - $6.95 Million	-300,000 Reduced 11.45%	2,319,968 $49.8 Million
Q4 2021 Feb 14, 2022	SELL	$42.59 - $55.02 $4.7 Million - $6.07 Million	-110,295 Reduced 4.04%	2,619,968 $117 Million
Q4 2020 Feb 16, 2021	SELL	$36.89 - $93.56 $120 Million - $304 Million	-3,250,000 Reduced 54.35%	2,730,263 $229 Million
Q3 2020 Nov 16, 2020	SELL	$23.13 - $38.84 $46.3 Million - $77.7 Million	-2,000,000 Reduced 25.06%	5,980,263 $214 Million
Q4 2019 Feb 13, 2020	SELL	$14.4 - $19.99 $366,969 - $509,425	-25,484 Reduced 0.32%	7,980,263 $139 Million
Q1 2019 May 14, 2019	SELL	$17.99 - $24.65 $16.4 Million - $22.5 Million	-913,002 Reduced 10.24%	8,005,747 $186 Million
Q4 2017 Feb 14, 2018	BUY	$15.04 - $21.45 $134 Million - $191 Million	8,918,749	8,918,749 $139 Million

227

119M

60.6K

48.4K

Ticker DNLI
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 134,174,000
Market Cap $2.88B
Description
Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutic candidates for neurodegenerative diseases in the United States. It offers leucine-rich repeat kinase 2 (LRRK2) inhibitor product candidate, including BIIB122/DNL151, a small molecule inhibitor, which is in phase I and phase Ib clinical trials for the treatm...

Get notified when there are updates to the investment portfolio of Flagship Pioneering Inc., based on Form 13F filings with the SEC.

Stay updated on Flagship Pioneering Inc. with notifications on news.